Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study

Published:2020-11 Issue:6 Volume:21 Page:e567-e571
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Luciani Andrea,Marra Antonio^ORCID,Toschi Luca,Cortinovis Diego,Fava Sergio,Filipazzi Virginio,Tuzi Alessandro,Cerea Giulio,Rossi Sabrina,Perfetti Vittorio,Rossi Antonio,Giannetta Laura,Sala Luca^ORCID,Finocchiaro Giovanna,Pizzutilo Elio Gregory^ORCID,Carelli Stephana,Agustoni Francesco,Cergnul Massimiliano,Zonato Sabrina,Siena Salvatore^ORCID,Bidoli Paolo,Ferrari Daris

Funder

Università degli Studi di Milano

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials;Gridelli;J Clin Oncol,2018

3. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer;Früh;J Clin Oncol,2008

4. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10;Pepe;J Clin Oncol,2007

5. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial;Quoix;Lancet,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

2. Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol;Cochrane Database of Systematic Reviews;2024-07-03

3. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study;Clinical Lung Cancer;2024-07

4. The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review;Translational Lung Cancer Research;2023-11

5. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer;Oncology Letters;2023-05-03